@article{3094828,
    title = "Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer",
    author = "Dimitriadis, E. and Trangas, T. and Milatos, S. and Foukas, P.G. and Gioulbasanis, I. and Courtis, N. and Nielsen, F.C. and Pandis, N. and Dafni, U. and Bardi, G. and Ioannidis, P.",
    journal = "International Journal  of Cancer",
    year = "2007",
    volume = "121",
    number = "3",
    pages = "486-494",
    issn = "0020-7136",
    doi = "10.1002/ijc.22716",
    keywords = "messenger RNA;  oncofetal antigen;  protein crd bp;  protein imp1;  RNA binding protein;  unclassified drug, adult;  aged;  article;  cancer recurrence;  cancer survival;  colon cancer;  correlation analysis;  female;  human;  human tissue;  immunohistochemistry;  intestine crypt;  major clinical study;  male;  metastasis;  outcome assessment;  prediction;  priority journal;  protein expression;  protein localization;  reverse transcription polymerase chain reaction;  tissue distribution, Adult;  Aged;  Aged, 80 and over;  Colonic Neoplasms;  Female;  Gene Expression;  Humans;  Immunohistochemistry;  Intestinal Mucosa;  Male;  Middle Aged;  Prognosis;  Reverse Transcriptase Polymerase Chain Reaction;  RNA, Messenger;  RNA-Binding Proteins",
    abstract = "The oncofetal CRD-BP/IMP1 RNA binding protein regulates post-transcriptionally a handful of RNA transcripts, implicated in cell adhesion and invadopodia formation and was recently identified as a target of the β-catenin/Tcf transcription factor that is constitutively activated in colorectal carcinomas (CRCs). The expression of CRD-BP/IMP1 was studied in normal adult intestines and CRCs. In normal mucosa, CRD-BP/IMP1 immunoreactivity was observed in few scattered cells located predominantly at or near the bottom of the crypts, whereas in CRCs the protein was detectable in tumor cells of 50% of the specimens analyzed. CRD-BP/ IMP1 mRNA expression was measured by qRT-PCR in 78 CRCs. Thirty-two (41%) of the specimens were negative or had negligible expression, whereas the remaining forty-six (59%) expressed a wide range of CRD-BP/IMP1 mRNA levels. CRD-BP/IMP1 mRNA expression correlated with that of the putative stem/progenitor cell marker Musashi-1 mRNA (p = 0. 035). CRD-BP/IMP1 positive tumors metastasized and/or recurred more frequently (p = 0.001) and its expression defined a group of patients with shorter survival (p = 0.014). Furthermore, in a multivariate analysis CRD-BP/IMP1 expression was found to be an independent predictor of survival (p = 0.015). For stage I & II patients, the differences in metastasis/recurrence and survival rates remained significant (p = 0.001 and 0.033, respectively). These findings indicate that CRD-BP/IMP1 positive tumors exhibit early disease dissemination and unfavorable prognosis. © 2007 Wiley-Liss, Inc."
}